Abstract
Retinitis pigmentosa (RP) encompasses a genetically diverse group of blinding inherited retinal diseases. In most subtypes the gene defect is expressed in the rod photoreceptors, yet in many affected individuals the cone photoreceptors undergo secondary degeneration, leading to loss of the remaining central vision. There is evidence that bioenergetic and oxidative stress are involved in this secondary cone loss. Photobiomodulation (PBM) uses low energy light in the far red or near-infrared spectrum to manipulate cellular activity. We have used a novel slit lamp-mounted retinal PBM laser to deliver precise energy levels to targeted retina. We showed that PBM laser attenuates oxidative and bioenergetic stress-induced photoreceptor loss in vitro and rescues cones in the rd1 murine model of RP. In a phase I trial (ACTRN12618000651280), foveal laser treatment was safe in humans with RP and temporarily recovered, on average, 5 letters of visual acuity.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ACTRN12618000651280
Funding Statement
This research was sponsored in part by a National Health & Medical Research Council grant: (APP1102568) Novel Photoreceptor Bioenergetics: Basic Science & Clinical Translation and a grant from the Ophthalmic Research Institute of Australia (ORIA): Rescuing Cone Photoreceptors in Retinitis Pigmentosa with Photobiomodulation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The experiments involving animals adhered to the Australian code for the care and use of animals for scientific purposes (the Code) and were approved by the University of Adelaide Animal Ethics Committee. The clinical study was conducted in accordance with the Declaration of Helsinki and was approved by the Central Adelaide Local Health Network Human Research Ethics Committee. Written informed consent was received from the participants prior to inclusion in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures: The authors have declared that no conflict of interest exists.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
